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ABSTRACT
Magnetic nanoparticles are effective delivery systems to target 
therapeutic genes by the attractive forces of magnetic fields. 
Curative effects depending on dose of nucleic acids or drugs 
increased, while cytotoxic effects minimized with these systems. 
In this study, a novel magnetic nanoparticle synthesis method 
was developed by combining advantages of microemulsion 
and multiple emulsion methods. Particle size, zeta potential, 
magnetization, complex formation with nucleic acids, DNase 
I protection ability, and cytotoxicity levels were examined. At 
last, magnetic nanoparticles were obtained with a promising 
synthesis method and it is determined that they are sufficiently 
small, non-toxic and have optimal surface properties for 
systemic delivery of nucleic acids. 
Keywords: Iron oxide, superparamagnetic, cationic magnetic 
nanoparticle, multiple emulsion, gene delivery, magnetofection
INTRODUCTION
To discover and process the genetic factors of diseases; and 
to deliver the therapeutic genes or materials to the concerned 
sites are two main approaches for gene therapy. With the 
rise of the gene therapy in last decades, generating effective 
gene delivery systems became one of the most prominent 
research area in pharmaceutical biotechnology. Non-viral 
gene delivery systems are preferred for this aim because of 
their low-cost, low immunogenicity and easy productions 
(1–3). Genetic material can be delivered by nanoparticles 
either with passive or active transport techniques. One of 
the active transport technique, which shows great promise 
for both in vitro and in vivo transfection is magnetofection. 
Magnetofection is defined as the nucleic acids delivery 
to cells, site-specifically guided by the attractive forces of 
magnetic fields acting on nucleic acid vectors, which are 
associated with magnetic nanoparticles (MNPs) (4, 5). 
MNPs should be coated with cationic materials to 
interact with DNA electrostatically. Most of the magnetic 
nanoparticle synthesis and coating methods include organic 
solvents or toxic agents (6–10) Another significant problem 
encountered in the synthesis of MNPs with iron compounds 
is the tendency of the reaction to synthesize non-magnetic 
iron compounds. This is mainly caused as a result of the 
effect of dissolved oxygen in the solutions. The dissolved 
oxygen must therefore be removed from the medium. 
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This removal can be performed by creating a nitrogen gas 
environment (11–15). Maintaining of the medium pH in 
the acidic range is another method (6, 16) For the multiple 
emulsion method that we developed, solutions of Fe+2 and 
Fe+3 are in the form of droplets surrounded by lipid layer of 
water/oil microemulsion. In this situation, the rate of contact 
with the external environment or atmospheric oxygen is 
lower. Another point is that the lipids participating in the 
microemulsion composition exhibit a protective effect by 
reducing the pH, as they contain fatty acids.
In this study, we developed a novel method based on 
physics and chemistry techniques to obtain non-toxic, 
biocompatible and targetable MNPs with optimal size and 
surface properties for gene delivery. Afterwards obtained 
MNPs were characterized and then MNP:DNA complexes 
were formed.  Protection efficiencies against DNase I enzyme 
and cytotoxicity levels were examined. 
MATERIALS
Plasmid DNA which encoding green fluorescent protein 
(pEGFP-C1) was used as genetic material (Invitrogen, 
California, USA). Ethanol, Tween 80, FeCl2, FeCl3 and 
Sodium dodecyl sulfate (SDS), were provided from Merck-
Co. (Hohenbrunn, Germany). Palmitic acid, Span 80, and 
dimethyldioctadecylammonium bromide (DDAB) were 
purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). 
Materials for agarose gel electrophoresis and cell culture 
reagents were purchased from Sigma-Aldrich Co. (St. 
Louis, MO, USA). Ultra-pure distilled water was used at all 
formulations. XTT cell proliferation assay kit was provided 
from Biological Industries (Beit-Haemek, Israel). Chinese 
Hamster Ovary (CHO) cell line was purchased from ATCC. 
METHODS
MNP Synthesis
In order to develop MNPs, microemulsion and multiple 
emulsion techniques were combined and MNPs were 
synthesized in the core of multiple emulsion. To obtain 
triangle phase diagram of oil in water (o/w) microemulsion 
is the first step of this method. Microemulsions were formed 
with palmitic acid as oil phase, Span 80 as non-ionic surfactant, 
ethanol as co-surfactant and Fe+2 and Fe+3 solutions as water 
phase (w1/o) over the lipid melting point (73oC).  Transparent 
regions belongs to w/o microemulsion area in phase diagrams 
were determined. DDAB was incorporated to the oil phase 
of the microemulsion for gaining cationic property to the 
MNPs. Then, obtained microemulsion were used as interior 
emulsion of multiple emulsion (w1/o/w2). Tween 80 was used 
as an outer surfactant and ultra-pure water used as an outer 
water phase (w1/o/w2). Afterwards 1 N NaOH was used to 
increase pH of the system. [OH-] ions leak to the interior 
water phase of the multiple emulsion. Therefore, magnetic 
iron oxide particles were synthesized in the core of cationic 
lipids regarding to the equation given below (6,18–21).
Fe2+ + 2Fe3+ + 8OH-à Fe3O4 + 4H2O
1 mL of hot multiple emulsion with magnetic core was 
taken in an injector and dropped into the ice-cold distilled 
water (0-2oC). MNPs were formed when multiple emulsion 
droplets met with cold water (MNP-Pa) (22–24). A neodium 
magnet was used for separation of MNP-Pa. MNP-Pa washed 
with distilled water for two times and the characterization 
studies were carried on (6,19,25).
To understand the effects of formulation on magnetization, 
one formulation (NP-Ø) was prepared as same as described 
above but ultra-pure water used instead of (1M Fe+2) and 
(2M Fe+3) solutions as the interior water phase. MNPs were 
also synthesized by a well-known co-precipitation method 
(MNP-CoP) (26).
Preparation of MNP:DNA Complexes 
MNP:DNA complexes were formed by mixing different ratios 
of pEGFP-C1 (0.1 µg/mL) and cationic MNP-Pa suspension 
for 30 minutes at 25oC. The blocking effect of MNP-Pa on 
the electrophoretic mobility of pEGFP-C1 was examined on 
agarose gel electrophoresis to determine optimal complex 
ratio (27,28). 
Size and Zeta Potential Measurements 
The particle size and zeta potential of MNPs and MNP:DNA 
complexes were determined with dynamic light scattering 
(DLS) method by using Zetasizer Nano ZS  (Malvern 
Instruments, Worcestershire, U.K.). Experiments were 
carried out at least in triplicate and standard deviations were 
calculated.
Magnetization measurements
Magnetic properties of nanoparticles were evaluated by using 
Lakeshare Vibrating Sample Magnetometer (VSM). 
DNase I Protection Study 
DNase  I was  added  to  MNP:DNA  systems  to  a  final 
concentration  of  1 IU DNase  I/2.5  µg pDNA, and the 
mixtures were incubated at 37oC for 30 min. Afterwards 
10% (w/v) SDS solution was added to the samples to a 
final concentration of 1% (w/v) to release pEGFP-C1 from 
the complex (1,29,30). Samples were then analyzed by 
electrophoresis on %1 agarose gel (containing %0.5 ethidium 
bromide) for 1 hour at 100 volts. The bands were visualized 
with a transilluminator (Biocapture, Vilber Lourmat).
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Cytotoxicity
CHO cells were seeded in a 96 well plate (6x103 cells per 
well) 24 h before the cytotoxicity test. Various volume of 
MNP-Pa and MNP:DNA complexes prepared within 100 μL 
DMEM media without serum. Culture media was aspirated, 
and the prepared samples were added to the wells. After 24 
h incubation at 37 °C and 5% CO2, XTT cell proliferation 
test was examined. Cell viability was calculated with specific 
absorbance corresponding to control group. Experiments 
were carried out at least in triplicate and standard deviations 
were calculated.
RESULTS AND DISCUSSION
In the method that we developed, the iron compounds are 
in the form of droplets in limited volume reaction pools, 
within the inner water phase of multiple emulsions. As the 
droplet size is limited by the reaction volume for production 
of MNPs, the dimensions also become more controllable. 
For this purpose, firstly w/o microemulsions were prepared. 
The w/o microemulsion area was determined by the aid of 
triangle phase diagram and transparent water in oil systems 
were formed (Figure 1). Formulation which has the largest 
volume of inner water phase was selected in the region of 
transparent systems. Micelles, liquid crystals and reaction 
derivate were removed and MNPs were collected by using a 
neodium magnet (Figure 2).  Characterization studies were 
performed as described in the methods.
Figure 1. Triangular phase diagram of w/o microemulsion 
formed with palmitic acid as oil phase, Span 80 as non-
ionic surfactant, ethanol as co-surfactant and Fe+2 and Fe+3 
solutions as water phase. Green area shows transparent w/o 
microemulsion region.
Figure 2. Optic photographs of obtained MNPs. MNP-Pa 
suspension (A) and magnetic separation of MNPs by using 
a neodium magnet (B). 
Magnetization of MNPs were analyzed by VSM. The magnetic 
properties such as saturation magnetization (Ms), remanent 
magnetization (Mr) and coercivity (Hc) were evaluated from 
the magnetization hysteresis of MNPs. As seen in Figure 3, 
MNPs are in paramagnetic behavior and Mr and Hc values 
are approximately zero. Although saturation magnetization 
of MNP-CoP is higher than the coated samples that we 
prepared, MNP-Pa has reasonably sufficient Ms values for 
magnetic targeting of nucleic acids (2, 7, 24, 31, 32). Ms value 
was measured 20 emu g-1 for lipid coated MNP-Pa while 35.2 
emu g-1 for MNP-CoP. 
Figure 3. Magnetization hysteresis loops for MNP-Pa, MNP-
CoP, and NP-Ø.
Particle size, polydispersity index and zeta potential values 
of MNPs were measured for characterization studies (Table 
1). MNP-CoP and MNP:DNA complex (3:1, v/v) were also 
prepared for characterization and comparison.
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Table 1.  Characterization of MNP-Pa, MNP-CoP and 
MNP:DNA Complex
Formulation Particle Size 
(nm) (±SD)
PDI 
(±SD)
Zeta Potantial 
- ζ (mV) (±SD)
1 MNP-Pa 21.75 
(0.153)
0.234 
(0.008)
19.24 (1.5)
2 MNP-CoP 9.52 (0.204) 0.338  
(0.045)
-25.9 (2.15)
3 MNP:DNA 
Complex 
(3:1, v/v) 
35.56 
(0.461)
0.486 
(0.004)
4.71 (0.656)
MNPs were produced in nano-scale size. Particle size was 
measured smaller than 30 nm and it is found appropriate 
to superparamagnetic character (15, 31, 33). The increase 
of particle size was determined for in situ coated MNP-Pa 
samples comparing to the MNP-CoP while both MNP-Pa 
and MNP:DNA complex were found sufficiently small to 
traverse the microvascular system. Therefore obtained MNPs 
are suitable for systemic delivery (31, 34, 35). PDI values 
showed that more homogeneous particle size distribution 
was obtained for the MNP-Pa compared to MNP-CoP and 
MNP:DNA complex. 
When MNPs used without coating, they are cleared from 
body in a short time by the immune system. While their 
biocompatibility is a positive trait, they need to be coated 
with polymers or lipids in their applications as a delivery 
systems for drug or genes (2, 6, 7, 31, 36). In addition to the 
coating process, it requires a second purification step (37).
MNPs synthesized in multiple emulsions appear in the form 
of solid lipid nanoparticles. Since the synthesis of MNPs 
spontaneously ensures the production in lipid coated form 
there is no need an extra coating process as well as following 
purification steps. In the system that we developed, cationic 
lipid coating of the MNPs was ensured by the incorporation 
of DDAB in the oil phase of the microemulsion. Cationic 
zeta potential (19.24 mV) value was evaluated as a proof of 
cationic lipid coating after washing and magnetic separation 
processes (13, 38, 39).  
Cationic lipid coating allows MNP-Pa to form complexes 
with oppositely charged molecules via electrostatic 
interactions. Nucleic acids are negatively charged molecules 
because of their phosphate groups (28, 29, 40, 41). MNP-
Pa were formed complexes with pEGFP-C1 as genetic 
material. Optimal complex ratio which had protective effect 
on pEGFP-C1 against DNase I enzyme was determined by 
agarose gel electrophoresis (Figure 4). 
Figure 4. Agarose gel electrophoresis of MNP:DNA 
complexes. 1. pEGFP-C1, 2. pEGFP-C1+ DNaz I, 3.Ø, 
4,5,6,7,8, respectively MNP:DNA (1:1, 2:1, 3:1, 4:1, 5:1) (v/v) 
+  DNaz I+ %10 SDS, 9,10,11,12,13, respectively MNP:DNA 
(1:1, 2:1, 3:1, 4:1, 5:1) (v/v) + %10 SDS, 14,15,16,17,18, 
respectively MNP:DNA (1:1, 2:1, 3:1, 4:1, 5:1) (v/v), L: Linear, 
N: Nick, SC: Supercoiled. 
Formation of compact complex is important issue for gene 
delivery systems as well as release of the nucleic acids from 
the complex. Release of the nucleic acids is required for 
gene expression in the cell (3, 28, 42). For this purpose SDS 
which is a negatively charged detergent molecule was used. 
Affinity of SDS to the cationic nanoparticles is higher than 
nucleic acids and final concentration of 1% SDS is sufficient 
to release nucleic acids from the complex (43). 
Figure 4 features the agarose gel electrophoresis of resistant 
pEGFP-C1 in the complex with the increasing amounts 
of MNP-Pa against the degradation of DNase I enzyme. 
Complex formation demonstrated on band lanes 14-18 . It 
was observed that, the blocking effect of MNP-Pa on the 
electrophoretic mobility of pEGFP-C1 was started from the 
well 16 (MNP:DNA complex ratio  of 3:1, v/v). The band on 
lane 6 demonstrated that, MNP:DNA complexes prepared at 
3:1 (v/v) ratio was able to protect pEGFP-C1 against DNase 
I enzyme degradation when compared with pEGFP-C1 on 
lane 1. Release of pEGFP-C1 with the same complex ratio 
was shown on lane 11 and it was found sufficient.
Increasing volume of MNP-Pa and MNP:DNA (3:1, v/v) 
complexes were evaluated for cytotoxicity test. After 24 h 
incubation at 37°C and 5% CO2, XTT cell proliferation test was 
examined and % cell viability was calculated corresponding 
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to control with specific absorbance. Than results for all 
formulation groups were analyzed with graphical data as 
shown in Figure 5. 
Figure 5. % Viability of CHO cells at increasing doses (μl/
well) of MNP-Pa (A) and MNP:DNA complex (3:1, v/v) (B).
Cytotoxicity of MNP-Pa and MNP:DNA complexes were 
determined on CHO cells. No significant cytotoxicity was 
observed on CHO cells in the concentration range of 4-8 µl/
well for MNP-Pa and all the applied doses for MNP:DNA 
complexes. Cell viability drops lower than 60% after 8 µL for 
the MNP-Pa while it sustains around 80% for MNP:DNA 
complexes. Zeta potential of MNP-Pa measured as +19.24 
mV and it decreased to 4.71 mV for MNP:DNA complexes 
because of being in a complex with negatively charged nucleic 
acids. However, zeta potential reduction  is not associated 
with transfection efficiency of MNPs (26, 44). 
CONCLUSION
Obtained results showed that, MNPs have similar 
magnetization hysteresis compared with co-precipitation 
method and have superparamagnetic characteristics. Average 
particle size of MNPs-Pa and MNP:DNA (1:3, v/v) complex 
were measured 21.75 nm and 35.56 nm, respectively. No 
additional process for surface adjustments is needed with 
developed method. MNP-Pa are positively charged and are 
able to form complexes with pEGFP-C1 electrostatically. 
Zeta potential of MNP-Pa measured as +19.24 mV.  Agarose 
gel electrophoresis showed that DNA:MNPs complexes are 
able to release pEGFP-C1 from complex and also protect it 
from DNase I (1 IU/ 2.5 µg pDNA) enzyme degradation. 
Cytotoxicity of MNP-Pa and MNP:DNA were examined 
and it was found that cell viability sustains around 80% for 
MNP:DNA complexes. 
Consequently, a novel magnetic nanoparticle synthesis 
method which have appropriate particle size, zeta potential, 
and sufficient magnetic property for nucleic acid delivery 
was developed by combining advantages of microemulsion 
and multiple emulsion methods. Synthesized MNP-Pa are 
considered promising vehicles for non-viral gene delivery 
system for the treatment of genetic-based diseases.
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Gen aktarımı için katyonik lipid kaplı manyetik 
nanoparçacıkların çoklu emulsiyonlar kullanılarak 
yerinde üretimi 
ÖZ
Manyetik nanopartiküller manyetik alanın çekim kuvvetini 
kullanarak terapötik genleri etkili bir şekilde aktaran sistemlerdir. 
Bu sistemlerde, ilaç ve nükleik asit dozuna bağlı tedavi edici etki 
artırılırken, sitotoksik etkiler en aza indirgenir. Bu çalışmada 
mikroemulsiyon ve çoklu emülsiyon metotlarının avantajları bir 
araya getirilerek yeni bir manyetik nanopartikül üretim yöntemi 
geliştirilmiştir. Partikül boyutu, zeta potansiyeli, manyetizasyon 
değeri, nükleik asitler ile kompleks oluşumu, DNaz I’e karşı 
koruma yeteneği ve sitotoksisite derecesi araştırılmıştır. Son 
olarak, manyetik nanopartiküller gelecek vaat eden bir sentez 
yöntemi ile elde edilmiş ve nükleik asitlerin sistemik taşınması 
için yeterli derecede küçük boyutta, toksik olmayan ve ideal 
yüzey özelliklerine sahip oldukları belirlenmiştir.
Anahtar kelimeler: demir oksit, süperparamanyetik, katyonik 
manyetik nanopartikül, çoklu emülsiyon, gen aktarımı, 
manyetofeksiyon.
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